Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
ID07296497

A Randomized, Multicenter, Single-blind, Sham-controlled Clinical Trial on the Efficacy and Safety of Acupuncture in the Treatment of Refractory Rosacea

Led by Xiangya Hospital of Central South University · Updated on 2026-01-30

104

Participants Needed

1

Research Sites

12 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the effects of acupuncture on patients with refractory rosacea, a skin condition that causes persistent facial redness and flushing. This randomized, multicenter, sham-controlled clinical trial aims to determine whether acupuncture can effectively reduce facial erythema and flushing episodes compared to sham acupuncture. The study will enroll 104 participants aged 18 to 65 years who have not responded to conventional treatments. Participants will be randomly assigned to one of two groups: the acupuncture group or the sham acupuncture group. The acupuncture group will receive electroacupuncture treatment at specific points on the face, neck, and limbs with continuous waves at 1 Hz for 20 minutes per session, twice a week for 8 weeks (total of 16 sessions). The sham group will receive non-penetrating stimulation with blunt needles at the same locations and schedule, without electrical stimulation on facial points. The study consists of a 1-week baseline observation, an 8-week treatment phase, and an 8-week follow-up phase. Participants will attend five in-person visits at weeks 0, 4, 8, 12, and an online follow-up at week 16. During these visits, researchers will assess rosacea symptoms including redness, flushing severity, burning sensation, and telangiectasia using questionnaires and clinical evaluations. They will also monitor sleep quality and quality of life. Safety will be tracked through reports of treatment-related adverse events. The total participation duration is 17 weeks, including baseline, treatment, and follow-up periods.

CONDITIONS

Brief Title

Acupuncture for Refractory Rosacea: A Study on Its Effectiveness and Safety

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients diagnosed with refractory rosacea who have had at least 12 weeks of conventional oral medication without sufficient improvement
  • Age between 18 and 65 years, inclusive
  • Ability to understand the study, voluntarily agree to participate, sign informed consent, and comply with study procedures and follow-up
Not Eligible

You will not qualify if you...

  • Women who are pregnant, breastfeeding, or planning pregnancy soon
  • Patients with diabetes or moderate to severe systemic disease affecting liver, kidney, lung, or blood system
  • Patients with depression or other psychiatric disorders
  • Severe abnormal reactions to acupuncture (e.g., syncope, allergy)
  • Rosacea with nasal hypertrophy, other facial dermatoses, or systemic disease facial symptoms
  • Bleeding disorders or skin damage, infection, or lesions at acupuncture sites
  • Recent discontinuation of oral antibiotics less than 1 month ago or other medications as specified
  • Inability to comply with follow-up
  • Participation in other clinical trials within 1 month before screening
  • Any condition making participation unsuitable by investigator's judgment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Run-in Period

Duration - 1 week

Participants undergo a 1-week baseline observation period before starting treatment.

1 visit (in-person) at week 0 for baseline assessment

Treatment

Duration - 8 weeks

Participants receive either electroacupuncture or sham acupuncture treatment over 8 weeks, with two sessions per week.

16 treatment sessions and 3 in-person assessment visits at weeks 4 and 8

Follow-up

Duration - 8 weeks

Participants are followed for 8 weeks after treatment to assess long-term effects and safety.

2 in-person visits at weeks 12 and 16 (week 16 follow-up is online)

Trial Site Locations

Total: 1 location

1

Xiangya Hospital of Central South University

Changsha, Hunan, China, 410000

Actively Recruiting

Loading map...

Research Team

B

Ben Wang

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here